SBT-11-5301 / Sonoma Biotherapeutics - LARVOL DELTA

Second generation CD2-targeting LFA-3 fusion protein SBT115301 to restore immune homeostasis in autoimmune disease. (PubMed, iScience) - "Anti-drug antibodies decreased exposure of SBT115301 in some participants without affecting the pharmacodynamics. These data support further study of SBT115301 as a monotherapy or in combination with other drugs in autoimmune indications."

Journal • Immunology • Inflammation • CD2 • CD4 • CD58

Study of Single Doses of SBT115301 in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Sonoma Biotherapeutics, Inc. | Active, not recruiting ➔ Completed | Trial completion date: Jun 2024 ➔ Jan 2024 | Trial primary completion date: Jun 2024 ➔ Jan 2024

Trial completion • Trial completion date • Trial primary completion date

Study of Single Doses of SBT115301 in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Sonoma Biotherapeutics, Inc. | Trial completion date: Jan 2024 ➔ Jun 2024 | Trial primary completion date: Jan 2024 ➔ Jun 2024

Trial completion date • Trial primary completion date

Study of Single Doses of SBT115301 in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Sonoma Biotherapeutics, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2023 ➔ Jan 2024 | Trial primary completion date: Aug 2023 ➔ Jan 2024

Enrollment closed • Trial completion date • Trial primary completion date

Study of Single Doses of SBT115301 in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Sonoma Biotherapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

Study of Single Doses of SBT115301 in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Sonoma Biotherapeutics, Inc.

New P1 trial